<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645797</url>
  </required_header>
  <id_info>
    <org_study_id>APR003-001</org_study_id>
    <nct_id>NCT04645797</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions</brief_title>
  <official_title>A Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics/ Pharmacodynamics of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apros Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apros Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal&#xD;
      cancer (CRC) with malignant liver lesions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      APR003 is a small molecule TLR7 agonist that concentrates in the GI, and liver with limited&#xD;
      systemic exposure. It is designed to increase the therapeutic window of a TLR7 agonist by&#xD;
      minimizing the side-effects associated with generalized systemic immune activation and&#xD;
      inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1 Dose Escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measure</measure>
    <time_frame>Up to one year</time_frame>
    <description>Determine Maximum Tolerated Dose and/or Recommended Dose within the test APR003 dose range</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to three years</time_frame>
    <description>Overall Response Rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Advanced Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>APR003 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This portion of the study will evaluate the safety and pharmacokinetics of a range of APR003 doses administered once a week for 21 days in subjects with advance colorectal cancer (CRC) with metastases to the liver and to determine the RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APR003</intervention_name>
    <description>This portion of the study further explores the clinical activity, safety, pharmacokinetics and pharmacology of APR003 monotherapy at the RP2D and to assess the antitumor activity of APR003 in subjects with unresectable CRC with liver metastases.</description>
    <arm_group_label>APR003 Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Must have disease that is considered non-surgically resectable.&#xD;
&#xD;
          -  Relapsed or persistent/refractory to at least two prior systemic treatment regimens&#xD;
             for locally advanced or metastatic disease considered to be standard-of-care (SOC).&#xD;
&#xD;
          -  Must have previously received an irinotecan or oxaliplatin-based therapy, as well as a&#xD;
             targeted antibody therapy for metastatic disease&#xD;
&#xD;
          -  Tumors that are MSI-H/dMMR must have previously received checkpoint inhibitor therapy&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Normal coagulation panel&#xD;
&#xD;
          -  Willingness to use effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or history of CNS metastases&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Weitzman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Apros Therapeutics, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trinh Le</last_name>
    <role>Study Director</role>
    <affiliation>Apros Therapeutics, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial.</last_name>
    <phone>858-345-6638</phone>
    <email>clinical@aprostx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Griffith</last_name>
      <phone>407-303-2800</phone>
      <phone_ext>1101783</phone_ext>
      <email>elizabeth.griffith@adventhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute Cancer Research Clinic</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaelyn Linski</last_name>
      <phone>980-441-1015</phone>
      <email>jlinkski@carolinabiooncology.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Deleon</last_name>
      <phone>210-580-9521</phone>
      <email>cdeleon@nextoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Deleon</last_name>
      <phone>210-580-9521</phone>
      <email>cdeleon@nextoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

